The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients
Launched by WEIZMANN INSTITUTE OF SCIENCE · Jul 23, 2023
Trial Information
Current as of April 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the gut bacteria and their effects on people with Irritable Bowel Syndrome (IBS), a common digestive disorder that affects many individuals worldwide. Researchers want to understand how changes in gut bacteria, along with what people eat, may contribute to IBS symptoms. They are particularly interested in the small molecules produced by gut bacteria and how these might impact gut health. The study will also look at the effectiveness of a specific diet called the low-FODMAP diet, which involves avoiding certain foods that can cause digestive discomfort.
To participate in this trial, individuals must be between the ages of 18 and 70 and cannot have taken antibiotics or probiotics recently, among other health-related criteria. Participants should not have certain chronic conditions, pregnancy, or psychiatric disorders. Those who join the study can expect to share information about their diet and gut health, and they will contribute to important research that could lead to better understanding and treatment of IBS. This trial is currently recruiting participants, and it aims to shed light on how diet and gut bacteria work together in managing IBS symptoms.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and Female
- • Age - 18-70
- Exclusion Criteria:
- • Consumption of antibiotics 2 months prior to the first day of the experiment.
- • Consumption of probiotic supplements 1 month prior to the first day of the experiment.
- • Type 1 or type 2 diabetes diagnosis.
- • Pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study.
- • Chronic disease - to the discretion of the study doctor.
- • Cancer and recent anticancer treatment.
- • Psychiatric disorders - to the discretion of the study doctor.
- • IBD (inflammatory bowel diseases).
- • Alcohol or substance abuse.
- • BMI \> 35.
Trial Officials
Eran Elinav, Prof
Principal Investigator
Weizmann Institute of Science
About Weizmann Institute Of Science
The Weizmann Institute of Science is a prestigious research institution located in Rehovot, Israel, renowned for its interdisciplinary approach to scientific inquiry. Established in 1934, the Institute is dedicated to advancing knowledge across various fields, including biology, chemistry, physics, and mathematics. Its cutting-edge research and innovation extend to clinical trials, where it collaborates with global partners to translate scientific discoveries into therapeutic applications. The Weizmann Institute's commitment to excellence in research and education makes it a leading sponsor of clinical trials aimed at improving human health and understanding complex biological processes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rehovot, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported